Fecal calprotectin level measurements in small bowel allograft monitoring: A pilot study

Transplantation

Volumn 85, Issue 9, 2008, Pages 1281-1286

  Akpinar, Edip ^a,b   Vargas, Jacinto ^a,b   Kato, Tomaoki ^a,b   Smith, Lesley ^b   Hernandez, Erick ^b   Selvaggi, Gennaro ^a,b   Nishida, Seigo ^a,b   Moon, Jang ^a,b   Island, Eddie ^a,b   Levi, David ^a,b   Ruiz, Philip ^b   Tzakis, Andreas G ^a,b  

^a UNIVERSITY OF MIAMI   (United States)

^b UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

Allograft monitoring; Calprotectin; Small bowel transplantation

Indexed keywords

CALGRANULIN; MARKER; METHYLPREDNISOLONE; OKT 3;

ACUTE GRAFT REJECTION; CLINICAL ARTICLE; CLINICAL STUDY; CONFERENCE PAPER; DRUG FECES LEVEL; EFFLUENT; ENTERITIS; ENZYME LINKED IMMUNOSORBENT ASSAY; GASTROINTESTINAL BIOPSY; GASTROINTESTINAL ENDOSCOPY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; ILEOSTOMY; INFLAMMATION; INTESTINE GRAFT; INTESTINE ULCER; MONITORING; PILOT STUDY; POSTOPERATIVE PERIOD; PREDICTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SAMPLE; SCREENING; SMALL INTESTINE; SMALL INTESTINE ALLOGRAFT;

FECES; FOLLOW-UP STUDIES; GRAFT SURVIVAL; HUMANS; ILEOSTOMY; INTESTINE, SMALL; LEUKOCYTE L1 ANTIGEN COMPLEX; MONITORING, PHYSIOLOGIC; PILOT PROJECTS; RETROSPECTIVE STUDIES; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 43449136778     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e31816dcea2     Document Type: Conference Paper

References (32)

1. Ruiz P, Kato T, Tzakis A. Current status of transplantation of the small intestine. Transplantation 2007; 83: 1.
2. Selvaggi G, Gaynor JJ, Moon J, et al. Analysis of acute cellular rejection episodes in recipients of primary intestinal transplantation: A single center, 11-year experience. Am J Transplant 2007; 7: 1249.
3. Kato T, Ruiz P, Tzakis A. Exfoliative bowel rejection - a dangerous loss of integrity. Pediatr Transplant 2004; 8: 426.
4. Sudan D, Vargas L, Sun Y, et al. Calprotectin: A novel noninvasive marker for intestinal allograft monitoring. Ann Surg 2007; 246: 311.
5. Hassanein T, Schade RR, Soldevilla-Pico C, et al. Endoscopy is essential for early detection of rejection in small bowel transplant recipients. Transplant Proc 1994; 26: 1414.
6. Garau P, Orenstein SR, Neigut DA, et al. Role of endoscopy following small intestinal transplantation in children. Transplant Proc 1994; 26: 136.
7. Kato T, Gaynor JJ, Nishida S, et al. Zoom endoscopic monitoring of small bowel allograft rejection. Surg Endosc 2006; 20: 773.
8. Tzakis AG, Kato T, Levi DM, et al. 100 multivisceral transplants at a single center. Ann Surg 2005; 242: 480.
9. Langhorst J, Elsenbruch S, Koelzer J, et al. Noninvasive markers in the assessment of intestinal inflammation in inflammatory bowel diseases: Performance of fecal lactoferrin, calprotectin, and PMN-elastase, CRP, and clinical indices. Am J Gastroenterol 2008; 103: 162.
10. Hille A, Schmidt-Giese E, Hermann RM, et al. A prospective study of faecal calprotectin and lactoferrin in the monitoring of acute radiation proctitis in prostate cancer treatment. Scand J Gastroenterol 2007: 1.
11. Montalto M, Santoro L, Curigliano V, et al. Faecal calprotectin concentrations in untreated coeliac patients. Scand J Gastroenterol 2007; 42: 957.
12. D'Inca R, Dal Pont E, Di Leo V, et al. Calprotectin and lactoferrin in the assessment of intestinal inflammation and organic disease. Int J Colorectal Dis 2007; 22: 429.
13. Konikoff MR, Denson LA. Role of fecal calprotectin as a biomarker of intestinal inflammation in inflammatory bowel disease. Inflamm Bowel Dis 2006; 12: 524.
14. Gaya DR, Lyon TD, Duncan A, et al. Faecal calprotectin in the assessment of Crohn's disease activity. QJM 2005; 98: 435.
15. Gearry R, Barclay M, Florkowski C, et al. Faecal calprotectin: The case for a novel non-invasive way of assessing intestinal inflammation. N Z Med J 2005; 118: U1444.
16. Hanai H, Takeuchi K, Iida T, et al. Relationship between fecal calprotectin, intestinal inflammation, and peripheral blood neutrophils in patients with active ulcerative colitis. Dig Dis Sci 2004; 49: 1438.
17. Lusitani D, Malawista SE, Montgomery RR. Calprotectin, an abundant cytosolic protein from human polymorphonuclear leukocytes, inhibits the growth of Borrelia burgdorferi. Infect Immun 2003; 71: 4711.
18. Tibble JA, Bjarnason I. Fecal calprotectin as an index of intestinal inflammation. Drugs Today (Barc) 2001; 37: 85.
19. Orlando A, Modesto I, Castiglione F, et al. The role of calprotectin in predicting endoscopic post-surgical recurrence in asymptomatic Crohn's disease: A comparison with ultrasound. Eur Rev Med Pharmacol Sci 2006; 10: 17.
20. Fagerberg UL, Loof L, Myrdal U, et al. Colorectal inflammation is well predicted by fecal calprotectin in children with gastrointestinal symptoms. J Pediatr Gastroenterol Nutr 2005; 40: 450.
21. Dolwani S, Metzner M, Wassell JJ, et al. Diagnostic accuracy of faecal calprotectin estimation in prediction of abnormal small bowel radiology. Aliment Pharmacol Ther 2004; 20: 615.
22. Roseth AG, Schmidt PN, Fagerhol MK. Correlation between faecal excretion of indium-111-labelled granulocytes and calprotectin, a granulocyte marker protein, in patients with inflammatory bowel disease. Scand J Gastroenterol 1999; 34: 50.
23. Roseth AG, Aadland E, Grzyb K. Normalization of faecal calprotectin: A predictor of mucosal healing in patients with inflammatory bowel disease. Scand J Gastroenterol 2004; 39: 1017.
24. Wassell J, Dolwani S, Metzner M, et al. Faecal calprotectin: A new marker for Crohn's disease? Ann Clin Biochem 2004; 41: 230.
25. Bunn SK, Bisset WM, Main MJ, et al. Fecal calprotectin: Validation as a noninvasive measure of bowel inflammation in childhood inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2001; 33: 14.
26. Kato T, O'Brien CB, Berho M, et al. Improved rejection surveillance in intestinal transplant recipients with frequent use of zoom video endoscopy. Transplant Proc 2000; 32: 1200.
27. Ruiz P, Weppler D, Nishida S, et al. International grading scheme for acute rejection in small bowel transplantation: Implementation and experience at the University of Miami. Transplant Proc 2006; 38: 1683.
28. Quintini C, Kato T, Gaynor JJ, et al. Analysis of risk factors for the development of posttransplant lymphoprolipherative disorder among 119 children who received primary intestinal transplants at a single center. Transplant Proc 2006; 38: 1755.
29. Selvaggi G, Sarkar S, Mittal N, et al. Etiology and management of alimentary tract ulcers in pediatric intestinal transplantation patients. Transplant Proc 2006; 38: 1768.
30. Loinaz C, Kato T, Nishida S, et al. Bacterial infections after intestine and multivisceral transplantation. The experience of the University of Miami (1994 -2001). Hepatogastroenterology 2006; 53: 234.
31. Ruiz P, Soares MF, Garcia M, et al. Lymphoplasmacytic hyperplasia (possibly pre-PTLD) has varied expression and appearance in intestinal transplant recipients receiving Campath immunosuppression. Transplant Proc 2004; 36: 386.
32. Pappas PA, Tzakis AG, Saudubray JM, et al. Trends in serum citrulline and acute rejection among recipients of small bowel transplants. Transplant Proc 2004; 36: 345.